Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mustang Bio

Request full access

A fortress biotech Company

Waltham, United StatesFounded 2015Biotech & Life Sciences

About Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company incorporated in 2015 and headquartered in Waltham, Massachusetts. A subsidiary of Fortress Biotech, Inc., the company is focused on developing and commercializing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. The company's business model centers on acquiring rights to these technologies through licensing or ownership, funding their research and development, and then either out-licensing them or bringing them to market directly. To advance its pipeline, Mustang Bio has established partnerships with prominent medical institutions such as Fred Hutchinson Cancer Center, City of Hope National Medical Center, and Mayo Clinic.

The company was founded by Fortress Biotech, Inc. The leadership team includes President and CEO, Manuel Litchman, M.D., who joined in April 2017 after serving as President and CEO of Arvinas, LLC. Dr. Litchman has an extensive background in oncology, including leading a collaboration on CAR T-cell therapies at Novartis. Michael S. Weiss serves as the Executive Chairman of the Board.

Mustang Bio's therapeutic pipeline features several key candidates. A major focus is on Chimeric Antigen Receptor (CAR) T-cell therapies. One of its lead programs is MB-106, a CD20-targeted autologous CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). Interim data from a Phase 1/2 trial of MB-106 showed a 90% overall response rate in patients with Waldenstrom macroglobulinemia, a rare blood cancer. The company is also developing CAR T therapies for solid tumors, including MB-101 for glioblastoma (GBM). Another program, MB-109, is a combination therapy using MB-101 (CAR T-cells) and MB-108 (an oncolytic virus) to treat glioblastoma. The strategy is to use the oncolytic virus to make the tumor microenvironment more receptive to the CAR T-cell therapy.

In the realm of gene therapy, Mustang Bio is developing MB-107, a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as "bubble boy disease". XSCID is a rare genetic disorder that is fatal within the first year of life if untreated. MB-107 has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). Phase 1/2 clinical trial data has been encouraging, supporting plans for a pivotal Phase 2 trial. The company's revenue is primarily derived from research and development activities and collaborations, as it is still in the clinical stage without commercial products. In May 2023, the company entered a strategic partnership with uBriGene (Boston) Biosciences, which included the sale of its Worcester manufacturing facility to reduce operating expenses and extend its cash runway.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2017

Mustang Bio in the Waltham ecosystem

Live from Dealroom

The Mustang Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Horizon Technology Finance Corporation
  • Runway Growth Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States90.5%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mustang Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mustang Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.